Saturday, October 25, 2014

Cipher Pharma adopts 5-by-5 mantra for future growth

Cipher Pharma adopts 5-by-5 mantra for future growth

September 16, 2014 by · Leave a Comment 

Tweet Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND), with newly installed CEO, Shawn O’Brien, has adopted a five-by-five strategy that sets objectives for its future growth. “I want to emphasize that this is not guidance, but within five years, we want our dermatology business in Canada to grow from $2-million this year to $50-million, we want to have […]

Cipher partner launches Absorica in U.S.

Cipher partner launches Absorica in U.S.

November 26, 2012 by · Leave a Comment 

Tweet Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) announced that its partner, Ranbaxy Laboratories, has begun the sales and promotion of Absorica, Cipher’s novel, patented, brand formulation of the acne medication isotretinoin for the treatment of severe recalcitrant nodular acne. “The launch of Absorica, our third commercial product, represents a major milestone for Cipher and we look forward […]

Cipher posts strong second quarter results

Cipher posts strong second quarter results

July 25, 2012 by · Leave a Comment 

Tweet Cipher Pharmaceuticals (TSX:DND; OTCBB: CPHMF) has posted second quarter profit of $200,000, compared with a year earlier loss of $500,000, on a 124% jump in revenue to $1.6-million. “It was an excellent quarter for the company both financially and from a product development perspective, highlighted by final FDA approval of our high-potential acne product, […]

Cipher posts Q1 profit on 168% revenue gain

Cipher posts Q1 profit on 168% revenue gain

May 4, 2012 by · Leave a Comment 

Tweet Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) achieved a profit of $125,000 in the first quarter this year, compared with a year earlier loss of $1.1 million, as revenue rose 168% to $1.8 million. “Revenue grew strongly in the first quarter based on Lipofen’s performance and early contributions from ConZip, which was recently launched in the U.S.,” […]

Cipher partner launches of Durela in Canada

Cipher partner launches of Durela in Canada

March 19, 2012 by · Leave a Comment 

Tweet Cipher Pharmaceuticals’ (TSX:DND; OTCBB:CPHMF) partner, Medical Futures, has launched Durela, an extended-release tramadol product, in key markets across Canada, with a dedicated sales force of about 22 representatives initially. “With sales of more than $41 million in 2011, the Canadian tramadol market remains robust, and we believe Durela’s attributes, including once-daily dosing, fast onset […]

Health Canada accepts Cipher acne filing for review

Health Canada accepts Cipher acne filing for review

January 30, 2012 by · Leave a Comment 

Tweet Health Canada has accepted for review a New Drug Submission by Cipher Pharmaceuticals (TSX: DND) for its CIP-Isotretinoin, a novel, patented formulation of the acne medication isotretinoin. The company expects a response from Health Canada in the first quarter of 2013. “Health Canada’s acceptance moves us a step closer to the commercialization of CIP-Isotretinoin […]

Zacks starts Cipher at outperform

Zacks starts Cipher at outperform

January 5, 2012 by · Leave a Comment 

Tweet Zacks Investment Research has initiated coverage of Cipher Pharmaceuticals (TSX:DND) with an “outperform” rating and 12-month price target of $2.25. The stock closed at 64 cents on Wednesday. “Based on our model, the stock is currently trading below the net present value of the cash flows from Lipofen and ConZip /Durela, plus the cash […]

Cipher readies regulatory filings for acne product

Cipher readies regulatory filings for acne product

October 26, 2011 by · Leave a Comment 

Tweet Cipher Pharmaceuticals (TSX:DND) is on track to file Health Canada and FDA submissions this quarter for its high-potential acne product, CIP-Isotretinoin, which is expected to trigger a $1 million milestone payment from its U.S. partner. The FDA review under PDUFA is expected to be six months. “With Lipofen generating steady revenue and our tramadol […]

Cipher signs up Canadian distributor for Tramadol

Cipher signs up Canadian distributor for Tramadol

September 26, 2011 by · Leave a Comment 

Tweet Cipher Pharmaceuticals (TSX:DND) has entered into a distribution and supply agreement with Medical Futures, a closely held Canadian pharmaceutical company, for the marketing of Durela in Canada. Durela is Cipher’s once-daily capsule formulation of tramadol, which has both immediate-release and extended-release components for the treatment of moderate-to-moderately severe chronic pain in adults. “This agreement, […]

Email Newsletters with Constant Contact
Google+